Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 10/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10314870 | 0.82 | GRM5 (0.56) | GRM5 | |
| SCHEMBL10314885 | 0.81 | GRM5 (0.44) | GRM5HRH3CYP11B2CYP1A2 | |
| SCHEMBL10009266 | 0.80 | GRM5 (0.56) | GRM5 | |
| SCHEMBL10314869 | 0.77 | MAOA (0.53) | GRM5CYP11B2CYP1A2 | |
| SCHEMBL10314931 | 0.75 | GRM5 (0.48) | GRM5CYP11B2 | |
| SCHEMBL2669108 | 0.71 | HTR1A (0.44) | GRM5 | |
| SCHEMBL10008711 | 0.71 | GRM5 (0.55) | GRM5HRH3 | |
| SCHEMBL17131111 | 0.70 | MEN1 (0.40) | GRM5CYP11B2 | |
| SCHEMBL10314882 | 0.69 | POLB (0.48) | GRM5 | |
| SCHEMBL799132 | 0.68 | MEN1 (0.38) | GRM5CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853237-B2 | Naphthyridinone analogs as mGluR5 positive allosteric modulators | VANDERBILT UNIVERSITY (US) | 2014-10-07 | — | — | US | disclosed |
| US-8853237-B2 | Naphthyridinone analogs as mGluR5 positive allosteric modulators | VANDERBILT UNIVERSITY (US) | 2014-10-07 | — | — | US | disclosed |
| US-20120172391-A1 | NAPHTHYRIDINONE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2012-07-05 | — | — | US | disclosed |
| US-20120172391-A1 | NAPHTHYRIDINONE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2012-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172391-A1 | NAPHTHYRIDINONE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS | GRM5, GRIK5, GRM1 | GRM5 1/4885HRH3 784/4885CYP11B2 2221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.